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MICROFLUIDIC EVAPORATOR CHIP FOR CONCENTRATION OF 
  
BACTERIAL SAMPLES FOR SERS IDENTIFICATION 
 
JARED C. SAFFIE 
ABSTRACT 
Sepsis is a serious medical condition in which a person becomes infected with 
bacteria in his or her bloodstream. The symptoms of sepsis are a result of the immune 
system’s interaction with the infecting agent.  Currently, to diagnose a patient with sepsis, 
a blood sample must be collected and cultured for 24-48 hours before the infection can be 
confirmed.  In the meantime, a broad-scope antibiotic is administered which may or may 
not be effective in treating the patient. If the antibiotic is ineffective, a different antibiotic 
must be chosen.  When the results of the blood culture are available, a narrow scope 
antibiotic, appropriate to treat the infection is administered[1].   However, sepsis has a 
mortality rate of 18-30% depending on the infecting agent and the treatment is highly 
time sensitive [2].  Within 24 hours, they syndrome may progress to septic shock and 
mortality rates reach 50% [3].  Therefore, it is important to quickly and correctly identify 
the infecting agent and provide immediate targeted treatment [1, 4-6]. 
Surface Enhanced Raman Spectroscopy (SERS) can be used to quickly identify 
and distinguish between different bacterial strains; however it requires higher bacterial 
concentrations than are present in the blood during the early stages of sepsis.  A 
microfluidic evaporator chip has been developed to concentrate bacteria samples from 
4µl to 100nl; the chip has been evaluated for concentration efficiency on Escherichia coli 
and methicillin-sensitive Staphylococcus aureus.  Various blocking methods using bovine 
v 
serum albumin (BSA) have been tested to reduce bacterial adhesion to the chip and have 
improved bacterial recovery to around 70% for both strains tested.  Ongoing tests are 
being performed to improve bacterial recovery and sample purity for identification. 
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Chapter 1: Introduction and Background 
1.1 Sepsis 
Systemic Inflammatory Response Syndrome (SIRS) can be defined as the 
presence of two or more of the following symptoms: fever (temperature greater than 
38OC) or hypothermia (less than 36OC), elevated heart rate (pulse greater than 90 beats 
per minute), increased respiratory rate (greater than 20 breaths per minute), and irregular 
white blood cell count (greater than 12,000/mm3 or less than 4000/mm3) [2].  When it is 
suspected that these symptoms are caused by bacterial infection, the condition is known 
as sepsis. According to the Centers for Disease Control, bacterial infections such as these 
were the 10th leading cause of death in the United States in 2007.  Several other sources 
state that 750,000 cases of sepsis occur in the United States annually [2, 3, 7]. The 
mortality rates for sepsis range from 18% to 30% [2].   
The symptoms of sepsis are due to the interactions between the infecting 
organism and the body’s immune and inflammatory responses [8]. The body up regulates 
appropriate immune response, but eventually this response becomes unregulated, leading 
to a cascade which, if left untreated, will lead to the patient’s death [4]. When a patient is 
diagnosed as septic, the organism causing the infection must be identified in order to 
determine the most effective course of treatment.  Blood culture is typically used to 
confirm infection; however, depending on the growth rate of the organism, these results 
may take up to 2 days.  The results of this test give no strain identification information 
but simply confirm that the infection is bacterial.  In the meantime, a broad scope 
antibiotic is prescribed.  This antibiotic may improve the patient’s health; however, if the 
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antibiotic was not an appropriate choice for the infecting bacterium, the patient’s health 
will continue to deteriorate if the antibiotic was not an appropriate choice for the 
infecting bacterium [1]. 
The treatment of sepsis is highly time sensitive from the point of the initial 
infection.  Within 24 hours of infection coagulation abnormalities begin to occur in the 
patient [4].  Monocytes circulating in the blood stream become hypo-responsive to 
stimuli and lymphocytes begin to show increased rates of apoptosis [5, 6].  The later 
stages of the syndrome are known as severe sepsis and then septic shock.  When the 
patient progresses to severe sepsis, organ failure begins to develop in addition to 
hypoperfusion or hypotension.  The last stage in the progression is septic shock.  Here, 
the patient suffers from hypotension due to the septic infection.  Despite fluid monitoring 
and replenishing, hypotension persists in the patient at this stage of sepsis [2].  The 
mortality rate for patients experiencing septic shock is around 50% [3].  The multi-organ 
failure associated with septic shock can occur within 24 hours of initial septic 
presentation [2]. 
Given the extreme time dependence when dealing with a sepsis infection, it is 
extremely important to begin treatment as soon as possible.  Currently, treatment begins 
with the use of a broad scope antibiotic that is known to be effective in treating a wide 
range of infections.  This treatment is meant as a first course of treatment before more 
information regarding the infecting agent is determined and a narrow scope antibiotic can 
be chosen.  This method of treatment is educated guesswork which is a problem for two 
main reasons.  The first and most obvious is that the treatment may not work.  In this 
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case, a new antibiotic must be chosen.  The second is that a significant increase in 
antibiotic resistance has been seen in recent years, which is largely due to the over-
prescription of antibiotics [2].  
1.2 Antibiotic Resistance 
In 1941, most strains of Staphylococcus aureus were susceptible to penicillin G, 
but just 3 years later some strains of S. aureus could produce an enzyme to destroy 
penicillin.  As of 1987, 95% of S. aureus strains were resistant to penicillin and 
ampicillin [9].  Figure 1, adapted from Burton, et al. [10] shows an increasing trend in the 
percentage of S. aureus infections presenting as MRSA in U.S. intensive care units from 
1997 through 2007.  Although the cases of MRSA and MSSA have both been declining 
in recent years, the percent of S. aureus infections caused by MRSA has increased almost 
every year in the 10 year period studied,  representing an alarming trend that bacterial 
strains are becoming more resistant to the antibiotics used. The over-prescription of 
antibiotics has led to this increase in antibiotic resistance.  For example, the outbreak of 
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Figure 1.  Percent of S. aureus infections presenting as MRSA in U.S. intensive 
care units from 1997-2007. 
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MRSA infections has led to the increased use of the antibiotic vancomycin.  Vancomycin 
currently effectively treats MRSA infections, unlike penicillin or ampicillin, but its 
increased use has led other bacterial species such as enterococci to develop resistance to 
it.  Other bacterial species such as Escherichia coli (E. coli) have developed antibiotic 
resistance as well. Antibiotic resistant infection is more prevalent in hospital settings 
where the majority of sepsis infections occur.  For example only 30% of E. coli found in 
the community but 50% of E. coli found in hospitals are resistant to amoxicillin [11].   
Antibiotic resistance can occur in multiple ways.  Antibiotic resistance genes can 
be transferred between different types of bacteria through the use of bacteriophages or 
plasmids. Additionally, resistance can develop in an evolutionary manner through 
chromosomal mutation [12].  These mechanisms are a result of over prescription of 
antibiotics, prescription of the wrong antibiotic, or failure to complete a full course of 
antibiotic treatment.  Therefore, it is important in sepsis infections to quickly and 
correctly identify the bacteria causing the infection.  An earlier diagnosis can lead to 
targeted antibiotic therapy and improve the patient’s prognosis.  In addition, when the 
proper antibiotic is chosen, the risk of aiding in the evolution of antibiotic resistant 
bacteria is minimized. 
1.3 Project Goal 
Thus, a need exists for a rapid, point-of-care device for identifying the bacterial 
cause of sepsis infections. A multicenter approach to develop such a device is currently 
underway involving Fraunhofer Center for Manufacturing Innovation (CMI), the 
Klapperich lab of Boston University’s biomedical engineering department, the Ziegler 
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lab of Boston University’s chemistry department, and Jean Lee of Brigham and Women’s 
Hospital and Harvard Medical School.  The goal is to create a fully-automated system 
that will process a blood sample at the point-of-care and identify the bacterial strain 
within 30 minutes, allowing the doctor to make a more educated decision for the course 
of treatment.  By removing the waiting period for bacterial identification, the proper 
antibiotic may be prescribed at the point-of-care, thus reducing mortality and morbidity 
rates in septic patients.  The device is comprised of 3 main parts (see Figure 2).  The 
group at Fraunhofer CMI is responsible for selectively lysing the red blood cells in the 
patient’s blood sample while preserving and concentrating the bacteria in a macro-
concentrator from 10ml of blood to 4 µl.  The patient sample may contain 10-1000 cfu/ml 
of bacteria, depending on the infecting strain.  The Ziegler lab will use Surface Enhanced 
Raman Spectroscopy (SERS) to identify the bacteria in the final 100nl nano-concentrated 
sample. As shown in Figure 2, my work in the Klapperich lab links both of these steps 
and is the intermediate stage that will reduce the 4 µl sample from Fraunhofer CMI (stage 
one) to 100nl for SERS identification in stage three.  
 
Figure 2. Block diagram representation of three-part bacterial identification system.  
Blocks in red are the subject of this document. 
SERS is a vibrational spectroscopy that has been used for molecular identification 
[13]. SERS of bacteria strains has been well studied and documented.  It shows excellent 
sensitivity down to a single cell level and specificity to distinguish bacteria down to the 
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strain level [14, 15].  The substrate used for SERS bacterial identification is a 1mm 
diameter SiO2 substrate coated with 80 nm gold nanoparticles [15].  Although the SERS 
detection method exhibits high sensitivity, the illumination region of the SERS laser is 
quite small.  To increase the probability of strong SERS enhancement for rapid 
identification, the bacteria must be concentrated from physiological concentration to a 
volume and concentration appropriate for SERS identification.   
 
Figure 3. Process flow for bacterial concentration from 10 ml of whole blood to 100 
nl for transfer to the SERS substrate. 
Purifying bacteria from whole blood is a difficult process that requires the lysis of 
blood components while preserving viable bacteria.  The work flow is illustrated in 
Figure 3.  This process, being optimized by the Fraunhofer Center for Manufacturing 
Innovation, utilizes a standard laboratory centrifuge for blood lysis and initial bacterial 
concentration.  A 10 ml blood sample is drawn from the patient and added to 40 ml of a 
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lysis solution.  The blood and lysis solution are incubated at room temperature to lyse the 
blood components (steps 1 and 2).  The bacteria and any residual cell fragments are 
separated from the lysed blood cells by centrifugation (step 3).  The blood plasma and 
lysed cells are aspirated from the sample and the bacterial pellet is resuspended in fresh 
lysis solution to further purify the bacteria sample from the blood components (step 4).  
This process is repeated twice and a final 4 µl bacterial solution is produced, effectively 
concentrating the original sample by 25,000X (step 5). 
Although the first concentration step highly concentrates the sample, the resulting 
concentration is too low and remaining volume is too large for SERS integration.  The 
SERS substrate is hydrophilic, increasing the area over which the loaded sample will 
spread.  Microfluidics must be used to further reduce the sample volume to 100 nl (steps 
6-8).  It is this process of reducing the sample volume while preserving the bacteria that 
is the focus of this document.  The project goal is to create a microfluidic chip that will 
perform a 40X concentration of relevant bacteria samples (Escherichia coli and 
methicillin sensitive Staphylococcus aureus) [16, 17] from 4µl to 100 nl with greater than 
80% efficiency. 
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Chapter 2: Bacterial Adhesion Mechanisms 
One of the major challenges in creating a bacterial concentration device is to 
prevent the adhesion of the bacteria to the device itself.  Bacteria prefer to grow on solid 
surfaces rather than in liquid culture, making it difficult to concentrate a liquid sample of 
bacteria without losing a high percentage of the bacteria.  As microfluidic channels 
typically have large surface area to volume ratios, this is a serious consideration for 
developing a high efficiency bacterial concentration chip.  The mechanisms of bacterial 
adhesion are discussed in this chapter. 
Bacterial adhesion to plastic surfaces is a two-phase process.  The first phase 
involves chemical and physical interactions between the bacteria and the synthetic 
surface [18].  These interactions can be classified as long and short interactions.  The 
long interactions refer to van der Waals attractions, electrostatic charge, Brownian 
motion, and other effects on the bacteria that occur at distances of greater than 50 nm 
from the surface [19].  These interactions induce movement that can bring the bacteria in 
closer proximity with the surface where the short interactions have a stronger effect 
(distances of less than 5 nm).  At this distance, the interactions between the bacteria and 
the substrate are due to chemical, ionic, dipole, and hydrophobic interactions leading to 
bacterial adsorption [19, 20]. 
The second phase involves molecular interactions between the bacteria and the 
surface.  These processes tend to be irreversible and consist of specific interactions with 
proteins and molecular interactions between the bacteria and the wall.  Bacteria can 
produce surface proteins known as adhesins, which allow the bacteria to interact with and 
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adhere to other cells, proteins, and synthetic materials such as in implants or 
thermoplastic substrates in lab settings [21-23].    
Specific theories that describe bacterial adhesion include DLVO theory and 
thermodynamic theory.  DLVO theory describes the interaction between colloids and 
solid substrates by adding attractive forces such as van der Waals and subtracting 
repulsive forces such as electrostatic interactions and has been applied to bacterial 
adhesion; however, this theory does not account for the structure of the cell [18].  
Thermodynamic theory uses free energy as the main parameter for determining adhesion 
probability.  If free energy for the process per unit area is negative, adhesion is favored 
[24].  There are several thermodynamic theories, but each has limitations and assumes 
that the process is reversible, which it often is not.  Neumann’s theory states that the 
water contact angle of the surface is sufficient to determine the forces between the 
bacteria and the surface, but ignores the molecular interactions.  The Polar-Dispersion 
theory predicts the work done by the adhesion process to determine likelihood of 
adhesion but ignores specific interactions between the bacteria and proteins.  The electron 
donor theory states that hydrogen bonding and acid base interactions are responsible for 
bacterial adhesion [18].  These theories have been combined to form the extended DLVO 
theory which seeks to improve upon the DLVO theory by including hydrophobic 
interactions in the expression for adhesion energy.  This theory states that as cells 
approach a solid surface, they can be attracted through acid-base interactions from 
distances of 2 nm from the surface [25].    
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There are several specific factors contributing to bacterial adhesion including the 
environment (flow conditions, electrolyte concentration, and pH), substrate surface 
roughness, bacterial and material hydrophobicity, acid-base interactions, and electrostatic 
interactions.  Flow conditions are a dominant influence on the interactions between 
bacteria and the substrate surface.  Faster flow can result in lower adhesion, as the 
bacteria are pulled from the surface by the shear force exerted on them.  As the shear 
force increases, the density of the formed biofilm increases, but biofilm thickness 
decreases [26].  When the shear force is higher, it removes the bacteria that have adhered 
to other bacteria, but typically is not strong enough remove the bacteria that have 
irreversibly bound to the substrate, resulting in a denser, but thinner biofilm consisting of 
fewer bacteria [18]. 
The hydrophobicity of the bacteria and the substrate has a profound effect on 
adhesion [27].  Bacteria tend to be hydrophobic.  If the substrate is also hydrophobic it 
becomes easier to displace the water molecules between the bacterium and the substrate 
allowing the cell to come in contact with the substrate and adhere.  The hydrophobicity of 
the bacteria can be pH dependent.  It has been shown that the greatest adhesion to 
hydrophobic materials occurs when the pH of the liquid medium is between 2.2 and 4 
[28-30].  The pH of the liquid medium can also affect the hydrophobicity of the substrate 
affecting phase one interactions.  Material selection is important in the design of any 
device but in order to reduce bacterial adhesion, it is essential to choose less hydrophobic 
materials.  pH of the liquid medium is less concerning as the bacterial samples will be 
prepared in water or solutions buffered close to a pH of 7. 
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Surface roughness can also increase bacterial adhesion by increasing the available 
surface area for bacteria to bind [31].  An ultra-smooth surface has a base level of 
bacterial adhesion.  As the groove radius of the surface roughness increases, the bacterial 
adhesion will decrease because the surface area available for binding is reduced.  When 
the groove radius reaches the radius of the bacteria, the bacteria cell can fit into the 
groove, maximizing the contact between the cell and the substrate and allowing for strong 
adhesion, leading to a sharp increase in bacterial adhesion enhancement.  As the groove 
radius continues to increase, the binding enhancement decreases to the initial level when 
the grooves become much larger than the bacteria cells and appear locally ultra-smooth. 
As surface roughness can increase bacterial adhesion, chip manufacturing should be 
performed in a way that the channel surfaces are smooth and do not enhance adhesion.    
Finally, the surface charge of the bacteria can affect adhesion.  Bacteria tend to be 
negatively charged [32, 33].  Therefore, a negatively charged surface will repel bacteria, 
thus reducing adhesion.  For example, it was shown that coating hydrophobic substrates 
with negatively charged acrylic acid reduced adhesion to 1% of the substrate surface area 
[27]. 
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Chapter 3: Evaporation Mechanism and Design 
3.1 Evaporation Mechanism 
The microfluidic concentrator chip operates using an enhanced evaporation 
mechanism.  Evaporation in microfluidics for sample concentration has been described 
by several sources [34-36].  Evaporation is the phase change of a liquid to a gas at a 
temperature below the boiling 
point. Evaporation occurs 
naturally, but in standard 
laboratory conditions, occurs at 
a much slower rate than would 
be beneficial in this process.  The chip consists of a liquid flow layer molded in 
thermoplastic, an airflow layer, and a porous, hydrophobic membrane sandwiched 
between the two layers. By reducing the pressure on one side of the hydrophobic 
membrane, evaporation of the sample is induced at the gas/liquid.  The hydrophobicity of 
the membrane prevents the liquid sample from entering the pores.  As the sample 
evaporates, the gas molecules are able to pass through the pores in the membrane.   A 
meniscus forms and moves from the inlet of the chip to the outlet, dragging the bacteria 
in the sample.  This mechanism is illustrated in Figure 4, adapted from Zhang, et al, [34].  
The evaporation rate depends on the area of the exchange surface, and the mole fractions 
of liquid vapor both at the gas/liquid interface, and in the gas stream.  As evaporation is a 
surface phase change, the sample can only evaporate from surfaces exposed to the airflow 
through the hydrophobic membrane.  As the sample volume is decreased, this area of 
  
Convective Airflow 
Fluid Flow 
Figure 4. Enhanced evaporation mechanism 
driven by convective airflow. 
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exchange also decreases leading to a decreasing evaporation rate as the process 
progresses [34].   
3.2 Initial Design 
The evaporator chip described by Zhang, et al [34] was designed for a 100 µl 
input sample, reduced the sample volume to 500 nl, and was cast in 
poly(dimethylsiloxane) (PDMS).  The chip efficiently concentrated the bacteria samples, 
but was too large to be integrated with the macro-concentrator system. A new chip has 
been designed to reduce both the input and output volume of the original sample. 
The scaled down version of the concentrator chip has been designed to hold a 4 µl 
input sample and reduces the sample volume to 100 nl, a 25-fold reduction in input 
volume and a 5-fold reduction in output volume of the original chip.  The chip is 18 mm 
by 15 mm and is 1 mm thick.  The channel is 
serpentine and is 500 µm wide and 200 µm deep.  
The chip effectively reduces the sample size by 
40X.  The chip geometry appears in Figure 5.  The 
chip’s input port has a diameter of 2 mm enabling 
it to hold the entire 4 µl sample.  The output port 
diameter is 1 mm, the smallest hole-size available 
from Proto Labs, the injection molding company that produces the chips. 
The chip itself consists of three parts: a liquid flow channel molded in a 
thermoplastic material, a hydrophobic porous membrane, and a vacuum fixture that 
applies the negative pressure necessary to drive the evaporation.  The vacuum fixture 
5mm 
Figure 5. Top view of nano-
concentrator chip. (A) Input 
port. (B) Output port. 
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consists of a peg array machined in a polycarbonate block.  The array consists of 500 µm 
x 500 µm pegs that cover a 15 x 18 mm area – the dimensions of the chip.  The vacuum is 
applied through the peg array, sealing the chip to the fixture and creating the convective 
airflow necessary to drive the evaporation.  The pegs give structural support to the chip 
and membrane, aiding in the prevention of membrane separation from the chip and thus 
preventing sample leakage without fully obstructing sample exposure to airflow. The 
vacuum fixture appears in Figure 6.  The pegs cover approximately 50% of the airflow 
area which may reduce the evaporation speed. However, the pegs are designed to prevent 
the complete obstruction of airflow along the channel.  The pegs are the width of the 
channel and are also separated by a channel width.  When the chip is oriented on the peg 
array, at least half of the channel is exposed to the airflow enhancing the evaporation.  
While evaporation rates may be improved without the inclusion of the channel, it is 
equally important to prevent separation of the membrane from the chip to prevent sample 
loss.  
 
Figure 6. Vacuum fixture and peg array for sample concentration. 
 
5mm 50 mm 
mm 
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Chapter 4: Chip Fabrication and Material Selection 
4.1 Chip Materials and Fabrication 
The chip was tested using three test materials: Zeonex 690R (Zeon Chemicals 
L.P., Louisville KY), polystyrene, and poly(methyl methacrylate) (PMMA).  Zeonex was 
the first material tested.  These chips were produced through hot embossing on a Carver 
hot press.  To produce these chips, blank thermoplastic plaques were made from Zeonex 
690R pellets. Approximately 6 grams of pellets were used per plaque.  They were placed 
between two steel plates lined with kapton film.  Steel shims (0.74 mm thickness) were 
also placed between the plates to regulate the thickness of the plaques.  The plates and 
plastic pellets were placed on the lower platen of the hot press and brought into contact 
with the top platen, but no pressure was applied while the entire system equilibrated to 
390°F.  When the desired temperature was reached, 500psi was applied to the system.  As 
the pellets melted, this pressure gradually reduced to 0.  When the pressure reached 0psi, 
a pressure of 1000psi was applied.  Again, this pressure gradually reduced to 500psi and 
then was raised to 3000psi and held for 5 minutes.  After the 5 minute period, the 
pressure was released and the steel plates were removed from the hot press.  The plaque 
could then be removed from the steel plates and be used to mold the chip.  To mold the 
chip, a vacuum chamber was filled with an epoxy resin mold of the appropriate channel 
geometry, a Zeonex plaque, a piece of kapton film and silicone rubber.  The top of the 
vacuum chamber was sealed and placed on the lower platen of the hot press and then 
brought into contact with the upper platen and the system was allowed to equilibrate to 
315°F.  When this temperature was reached, 500psi was applied to the system for 8 
16 
minutes.  The chamber was removed from the hot press and allowed to cool at room 
temperature for 10 minutes.  The chamber was opened and the plaque containing 
embossed chips could be removed and cut into individual chips. 
The hot embossed chips often had inconsistencies or bubbles in them and were 
difficult and time consuming to make; therefore they were only used in initial proof of 
concept testing. 
Subsequent versions of the chip were injection molded by Proto Labs, Inc.  These 
chips were highly consistent and could be ordered in bulk making them both time and 
cost effective.  The first material tested was polystyrene.  Polystyrene was chosen for its 
optical clarity; however, it turned out to be a poor choice for the chip material.  It often 
broke down during the bonding process and the channels became roughened which led to 
poor bacterial recovery rates.   
The final material tested was PMMA.  This material was also chosen for its 
optical clarity and its relative inertness.  These chips proved to be the best of the 
materials tested.  Like the polystyrene chips, they were injection molded by Proto Labs, 
enabling cost and time effective chip manufacturing.  The PMMA chips held up well 
during the bonding process; therefore it was chosen as the chip material. 
The PMMA chips were sealed with the polypropylene membrane through solvent 
bonding.  The polypropylene membrane was laid flat on the lab bench.  Approximately 
40 µl of dichloromethane (Sigma Aldrich) was pipetted onto the membrane to fill an area 
slightly larger than the chip. Dichloromethane was chosen because it evaporates quickly 
and thoroughly and has been used as a means of bonding PMMA [37, 38]. The 
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dichloromethane was allowed to evaporate for approximately 10 seconds.  The chip was 
then placed, channel side down, on the membrane while pulling a vacuum through the 
chip from the inlet to aid in drying the dichloromethane.  The chip was held in place, with 
the vacuum applied for 15 seconds.  The chip was then filled with 4 µl of food coloring as 
a visual aid to test for leaks.  Finally, the chip was flushed with 40 µl of sterile water to 
remove any remaining traces of food coloring and dichloromethane, as other solvents 
may damage the chip by roughening its surface.   
To ensure that the dichloromethane used for bonding the chips was not having 
adverse effects on the bacteria, live-dead staining was performed on several samples 
which were imaged before and after evaporation in the chip.  For these experiments, E. 
coli and MSSA strains containing green fluorescent protein (GFP) on a plasmid were 
used so that live cells could be fluorescently visualized.  To simultaneously visualize the 
dead cells, 1 ml of culture was centrifuged at 13000rpm for 1 minute to pellet the cells.  
The growth media was aspirated and the cells were resuspended in sodium citrate. 
Approximately 15 µl of propidium iodide was added to the bacteria/sodium citrate 
suspension and the solution was allowed incubated at room temperature for 30 minutes.  
The propidium iodide stained the dead cells red to visualize them simultaneously with the 
live cells shown in green.  Representative images of these results appear in Figure 7. 
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Figure 7. Live-dead staining of E. coli before (left) and after concentration. Live 
cells appear green, dead cells appear red. (40x magnification) 
  
In the figure, the live cells appear green and the dead cells appear in red.  The 
photo on the left is a bacteria sample before concentration in the microfluidic chip.  
Although more dead cells exist after the evaporation process, no significant loss can be 
attributed to cell death.   
 A comparison of recovery rates of these three chip types appears in Figure 8.  
The initial experiments to evaluate chip materials were performed with a suspension of E. 
coli in LB broth.  The chips were prepared as previously described with Zeonex chips 
being hot embossed on the Carver hot press and polystyrene and PMMA chips being 
injection molded by Proto Labs.  In each case, the channels of the chips were filled with a 
1% BSA solution for 30 minutes to block the channels prior to introducing the bacterial 
sample.  Recovery rates were quantified by plating the output sample and comparing 
colony counts to the input sample.  PMMA yielded greater than 3-fold better percent 
recovery at 51% ± 7%SD than the other two materials and was chosen as the material for 
chip fabrication. 
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Figure 8. Chip material comparison in initial experiments with E. coli. All chips 
were blocked with a 1% BSA solution. N=5. 
For the hydrophobic membrane, several materials were chosen and tested, but 
only two were successful: polytetrafluoroethylene (PTFE, Teflon) (Sterlitech, Kent, WA) 
and polypropylene (PP) (Whatman).  Teflon was the initial material tested for the 
membrane.  Teflon is highly hydrophobic with an advancing water contact angle, 
θA
W
=105°.  In the initial experiment summarized in Figure 8, 50% of the bacteria were 
recovered, but 50% of the bacteria were lost during the evaporation process.  It was 
unknown if the bacteria had adhered to the chip or had died in the evaporation process.  
Quantitative plating was used to determine the recovery of viable bacteria. To determine 
the site of the majority of the bacterial adhesion, the samples were concentrated in the 
chip.  In addition to plating the output sample, the membrane was removed from the chip 
and both the chip and the membrane were placed on an LB agar plate and incubated at 
37°C for 24 hours.  More bacterial growth occurred the membrane had been plated, as 
bacteria adhere more readily to hydrophobic surfaces [18]; therefore, less hydrophobic 
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materials were chosen for testing. The materials tested were polypropylene, 
polycarbonate, polyvinyl difluoride, and cellulose acetate.  Polypropylene (θAW = 89.3°)  
the only material that was sufficiently hydrophobic to prevent sample leaking.  The other 
membrane materials were too hydrophilic and immediately became saturated by the 
sample.  Results from the comparison between the Teflon (1 µm pores) and 
polypropylene membranes (0.45 µm pores) appear in Figure 9.  Changing the membrane 
material from Teflon to polypropylene increased the recovery rate of MSSA to around 
85% ±15%SD. 
 
Figure 9. Comparison of PTFE and Polyproplyene membrane materials on MSSA 
recovery. N=3. 
 
4.2 Evaporation Experimental Design 
To test the efficacy of the device, the same experiment was performed to 
determine the percent of the bacteria sample that could be recovered from the device. A 
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bacteria culture was grown by inoculating 3 ml of sterile LB broth with a single colony 
taken from a streak plate.  E. coli K-12 and MSSA Wichita were used as model 
organisms in these studies.  The culture was incubated overnight (16-18 hours) at 37°C 
shaking at 220 RPM.  The concentration of the overnight culture was determined by 
taking an optical density (OD) reading on an Eppendorf BioPhotometer with an OD of 
1.0A corresponding to approximately 8 x 108 cfu/ml.  The linear region of the 
biophotometer output ranges from 0 to 3A, so a series of dilutions was made to obtain a 
2.5x104-5x104 cfu/ml solution, leading to 100-200 cfu in a 4 µl input sample.  The output 
from the macro-concentrator may be of a higher concentration depending on the 
organism causing the infection.  Low concentrations are used to test the micro-
concentrator because it is at these concentrations where high bacterial recovery is most 
important.  The chips were bonded as previously described and a piece of kapton tape 
was placed over the outlet to allow for evaporation only from the inlet side of the sample.  
The chip was placed on the vacuum fixture and filled with 4µl of the diluted sample.  The 
vacuum was applied and the sample was allowed to evaporate until the meniscus reached 
the outlet of the chip.  When the meniscus reached the output port of the chip, the 
vacuum was turned off and the kapton tape was removed. Given the increased 
hydrophilicity of the chip by the BSA and the hydrophobic nature of the pipette tip, the 
tip was primed by pipetting up and down in LB.  Pre-wetting the tip enabled for easier 
transfer of the 100 nl output sample.  The sample could then be removed by pipetting.  
The output sample was re-diluted in 150 µl of LB for ease of plating, and then transferred 
to an LB agar plate, spread, left to dry at room temperature and then incubated for 16 
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hours at 37°C.  Positive controls were plated in triplicate using 4 µl of the input sample 
on each of three plates and incubated overnight.  Negative controls consisting of the LB 
broth used to dilute the samples were also plated to be sure no contamination of reagents 
occurred.  After the 16 hour incubation period, the colonies on each plate were counted.  
To calculate the efficiency of the chip, the positive control plates were averaged together.  
These positive control counts were highly replicable with standard deviations typically 
ranging from 5 to 10% of the positive control mean.   The total number of colonies 
recovered from each chip were divided by the average of the positive control plates and 
multiplied by 100 to get a percentage: 
%		 = 	
#				
	#					
× 100% 
These percentages were averaged for chips prepared in the same way and compared to 
other chip preparation methods. 
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Chapter 5: Bacterial Recovery 
5.1 Blocking Agent Adsorption 
Protein adsorption onto solid substrates from aqueous solution is driven by a 
number of phenomena, particularly electrostatic interactions and hydrophobic 
interactions [39].  Like bacterial adhesion, protein adsorption can be described with a 
thermodynamic model in that adsorption is favored by a decrease in the free energy of the 
system [40].  For adsorption to occur, the proteins are brought into contact with the 
surface via mass transport (diffusion, convection, etc.).  Electrostatic interactions, while 
not strong enough to act on the protein from a distance, can have a large impact on 
adhesion to the surface when the protein is in close proximity to it.  When the substrate is 
hydrophobic, water molecules between the protein and the surface are easily displaced 
and the electrostatic charge can induce adhesion [41]. 
Hydrophobic interactions are the most important interactions involved in protein 
adsorption to solid surfaces.  Proteins tend to be amphipathic [42].  Although the 
hydrophobic residues typically reside in the interior of the protein structure, the 
hydrophilic surface of the protein favors the dissolving of the protein in water.  From an 
entropic standpoint, the interaction between the hydrophobic protein residues and water 
must be minimized.  Additionally, the interface between water and a hydrophobic surface 
is inherently ordered.  Entropy, therefore, favors interaction of the hydrophobic surface 
with the hydrophobic portion of the protein [41, 43]. 
Bovine serum albumin is a 66kDa globular protein that is commonly used as a 
blocking agent to prevent non-specific interactions between bacteria and a polymer 
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surface [43].  The focus of many experiments was to prevent adhesion of bacteria to the 
channels of the microfluidic chip.  Without blocking the chips, the recoveries were quite 
low.  For both MSSA and E. coli, the recovery rates typically varied from 10-30%, when 
the chips were unblocked.  Blocking experiments were performed through the use of 
well-known blocking agents: bovine serum albumin (BSA), Pluronic F-127, polyethylene 
glycol (PEG) (all Sigma-Aldrich), and powdered milk (Star Market).  Blocking solutions 
were made by suspending the proper amount of blocking agent in filtered deionized (DI) 
water and vortexing until it was completely dissolved.  Blocking agents were made fresh 
on each day of experiments. 
Blocking the channels of the chip was typically accomplished by filling the chip 
with the chosen blocking agent and letting it sit for 30 minutes before the experiment was 
run.  When the experiment was to begin, the blocking agent was vacuumed out of the 
chip using house vacuum.  Chip blocking was not followed by rinsing excess blocking 
agent out of the chip, a step often taken to ensure a more uniform deposition of blocking 
agent.  However, it was determined experimentally that washing the blocking agent from 
the chip reduced bacterial recovery and did not reduce variation among output samples.  
Blocking the chips coated the channels making them more hydrophilic and reducing the 
binding sites available to the bacteria.  As previously described, hydrophobic bacteria 
tend to stick more to hydrophobic surfaces, so blocking the channels is an easy way of 
reducing the bacterial adhesion by reducing the available binding sites. 
Initial blocking experiments were performed using concentrations of the blocking 
agents commonly found in literature.  For BSA, the initial concentration tested was 1% 
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(10 mg/ml).  Pluronic was tested at 0.05% (0.5 mg/ml), PEG at 0.75% (7.5 mg/ml), and 
milk at 0.5% (5 mg/ml) [20, 27, 31, 44].  The initial experiments compared the relative 
recovery rates of blocking with BSA and Pluronic as well as unblocked chips.   
Although blocking the chips with 1% BSA and 0.05% Pluronic significantly 
improved levels of bacterial adhesion over unblocked chips, the recoveries were still too 
low to be acceptable for the SERS method of detection (discussed in chapter 7.2).  A 
further course of experiments to improve bacterial recoveries was performed with BSA.  
The first of these experiments was performed to determine the optimal concentration of 
BSA to block the chips.  The concentrations tested were 1%, 2%, 4%, and 6%. There 
appeared to be no significant difference in recovery rates of MSSA among the BSA 
concentrations tested above 1%.  For completeness, this experiment was repeated for E. 
coli.  The results of both experiments appear in Figure 10.   
 
Figure 10. Percent recovery of MSSA and E. coli vs. BSA%. N=3. 
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An increase in the concentration of BSA did not improve recoveries for either 
bacterial type studied.  It has been shown that BSA adsorption to surfaces will typically 
form a monolayer at 1% concentration. At higher concentrations, crowding of the BSA 
molecules can occur, leading to conformational changes in the protein which may result 
two dimensional aggregations of BSA on the substrate surface.  This conformational 
change may reduce the ability of BSA to inhibit bacterial adhesion [43]. 
5.2 Hot Blocking 
To further test the effects of BSA on sample recovery, “hot blocking” 
experiments were performed, as it has been shown that protein adsorption can increase at 
elevated temperatures [45].  The first hot blocking experiments involved filling the chips 
with a 1% BSA solution and letting them sit for 30 minutes at 70°C. Additionally, chips 
were filled with 1% BSA and allowed to sit overnight (~16 hours) at both room 
temperature and at 37°C. A summary of the recoveries obtained by hot blocking the chips 
appears in Figure 11.  
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Figure 11. E. coli recoveries under various blocking temperatures and durations 
with 1% BSA. 
Given the positive results obtained by blocking the chips overnight, another 
experiment was performed to determine the optimum concentration of BSA to leave in 
the chip overnight.  6% BSA in the chip overnight provided the highest recoveries; 
however the blocking solution evaporated completely during blocking.  With lower 
concentrations of BSA, this was not a problem as the solution would dry and deposit the 
BSA onto the surfaces of the chip.  However, when the BSA concentration was 6% 
(60mg/ml), the BSA would recrystallize in the chip during drying, often physically 
obstructing the channel and restricting flow.  When the channels did not become 
obstructed, the recoveries were high; however, the incidence of chip failure was also 
much higher than usual.  Approximately one third of the chips produced were unusable.  
Higher recoveries were also obtained by using dried milk (0.5 mg/ml) to block the 
channels for 30 minutes prior to running the experiment.  Figure 12 summarizes the best 
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results obtained when blocking with BSA, PEG, and dried milk.  None of these blocking 
methods were chosen.  As previously mentioned, 6% BSA would clog the channels of the 
chip, 0.75% PEG did not produce high enough recoveries, and although dried milk gave 
higher than average recoveries, they were not high enough and it was thought that the 
milk might spoil in the chip during storage.  
 
Figure 12. E. coli and MSSA recovery summary of best methods for BSA, PEG, and 
dried milk. 
 
5.3 Dynamic Blocking 
In the experiments involving blocking the chips with BSA overnight, the blocking 
agent would be fully dried onto the surface of the chip.  It was hypothesized that when 
the bacterial sample was added to the chip, that some or all of the blocking agent was re-
dissolved into the bacterial sample resulting the channels being blocked while the sample 
was being run, a process known as dynamic blocking [45-47].  To test the effects of 
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dynamic blocking, the bacterial samples were prepared in BSA solutions ranging from 
1%-6%.  The chips remained unblocked and the samples were processed normally.  By 
preparing the samples in 6% BSA, we were able to achieve high recoveries of 
68±13%SD for MSSA and 71±9%SD for E. coli.  The excess BSA in the sample was 
able to coat the surface of the chip and may have also coated the surface of the bacteria.  
Since BSA tends to form a monolayer on solid surfaces, but coverage on hydrophobic 
surfaces reaches a maximum of about 53% of surface area covered, coating both the 
substrate and the bacteria may have helped reduce adhesion to any portion of the chip not 
coated in BSA [43].  A summary of BSA blocking conditions appears in Figure 13. 
 
Figure 13. Summary of BSA blocking methods and associated bacterial recoveries. 
 
  
0
20
40
60
80
100
120
6% BSA in
chip
overnight
6% BSA in
sample, 1%
BSA in
chip, 30
minutes
6% BSA in
sample,
unblocked
chip
6% BSA in
sample, 1%
BSA in chip
overnight
Av
er
ag
e 
Pe
rc
en
t R
ec
o
v
er
y
MSSA
E. coli
30 
Chapter 6: Sample Transfer 
For successful bacterial identification, the concentrated sample must be 
transferred to a localized, repeatable region of the SERS substrate.  The laser used for 
SERS excitation and detection has an illumination cross section of 2.5 µm by 20 µm.  
Therefore, it is desirable to transfer the majority of the sample into a small region to be 
detected by the laser.  Several transfer concepts were tested to determine the best transfer 
method for the sample.  Important considerations in choosing a transfer method were ease 
of use, ease of implementation, bacterial recovery, and sample distribution. 
6.1 Pressurized Air 
The first of these concepts consisted of a pressurized volume of air used to 
displace the sample at the output port, forcing it onto the SERS substrate.  This system is 
highly desirable because it is not comprised of any parts that would come in contact with 
the sample, allowing it to be reused for many samples.  The pressurized air system was 
characterized in several different ways.  To determine efficiency, the samples were 
evaporated on chip normally.  When the sample had reached its target output volume, a 
small burst of air was applied from the membrane side of the output port forcing the 
sample out and onto an agar plate.  Then, 100 µl of broth was added to the top of the 
sample and spread around.  The plates were incubated at 37°C for 16-18 hours and then 
the colonies were counted to determine the transfer efficiency.  The efficiency in these 
experiments was quite low, around 10%.  To evaluate the localization of this transfer 
method, the chips were filled with food coloring and the evaporation process was run 
normally.  At the end of the run, the puff of air was applied to the chip and the output 
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sample was directed downward toward a piece of parafilm.  The parafilm was used 
because it is hydrophobic and when the sample landed on the parafilm the spray pattern 
could be analyzed spreading effects. (See apparatus in Figure 14).   
 
 
 
Parafilm is also transparent so a ruler was lined up underneath it to measure the distance 
covered by the spray.  This was repeated at various distances from the parafilm as the 
distance of the SERS substrate from the outlet of the chip was as yet unknown.  However, 
even at the shortest distance of 750 µm, the spray pattern spanned a distance of 
approximately 2 mm.  Given the large area covered and the low bacterial recoveries, this 
method was abandoned in favor of other transfer mechanisms. 
6.2 Centrifuge Sample Transfer 
Another sample transfer method tested was the use of the centrifuge in removing 
the sample from the chip.  For testing purposes, a 96-well PCR plate was filled with 100 
µl of LB broth in well separated wells.  After the samples were evaporated on chip, the 
outlets of each chip were aligned with a well that was filled with broth and the chips were 
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Figure 14. Diagram of pressurized air transfer test fixture. 
32 
firmly taped down to the plate.  The plate was placed on a swinging plate holder and 
centrifuged for 1 minute at 1000rpm.  In the preliminary experiments performed using 
this method, the recoveries were low.  After realizing that the sample might be travelling 
back into the channel after concentration, the chips were inclined to better direct the 
sample out of the chip and into the collection well.  Three different angles, 15°, 30°, and 
45° were tested to find the optimal incline angle for the chip.  There was no significant 
difference in the bacterial recovery when the angle was 15° or 30°.  Therefore the 15° 
angle was chosen.  When the sample was removed from the chip in this way, the 
recoveries were equivalent to those obtained by pipetting the sample out of the chip, thus 
far the gold standard for sample transfer.  Thus, centrifuging was chosen as the transfer 
concept. 
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Chapter 7: Integration 
While it was important to produce a microfluidic chip that could concentrate 
bacteria samples with high efficiency, it was also important that the chip be integrated 
with the macroconcentator and the SERS substrate.  The first step in integration was to 
ensure that the testing done on the microfluidic concentrator chips would be valid when 
combined with the other systems.  To do so, samples from the output of the 
macroconcentrator would have to be successfully concentrated on the microconcentrator 
and samples from the microconcentrator would have to be evaluated on the SERS 
substrate. 
7.1 Macro-concentrator Integration 
Samples from the output of the macro-concentrator were tested in the micro-
concentrator chip.  It was hypothesized that the recoveries of samples that came from the 
output of the first stage macro-concentrator would be higher than those from coming 
directly from a broth laboratory culture. The function of the macro-concentrator is to 
process a 10 ml of blood in addition to bacteria.  The macro-concentrator’s function is to 
selectively lyse blood components while preserving the integrity of the bacteria.  While 
the macro-concentrator removes much of the cell debris, residual cell debris still exists in 
the sample.  The protein concentration in the sample after the macro-concentration 
process is much higher than the protein concentration in a cultured sample in LB.  It was 
hypothesized that these extra proteins would lead to higher recoveries in the samples 
taken from the macro-concentrator, even without blocking the chip.  The preliminary 
experiments of this type focused on simply testing the concentration mechanism on these 
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samples given their higher protein content and higher viscosity due to the presence of cell 
fragments in the sample.  In the preliminary experiments, the recoveries were lower than 
expected.  The samples were much more viscous than those cultured in broth and clogged 
the channels of the chip.  When the samples did not clog the chip, there would often be 
large chunks of cell debris left behind.  Most likely there were large deposits of bacteria 
trapped in these deposits, contributing to lower recoveries.  Furthermore, in the earliest 
experiments, there was more cell debris than could be concentrated to a volume of 100 nl.  
These samples eventually formed solid pellet of cell fragments and bacteria at the outlet 
consisting of more than 100 nl and could not be removed without resuspending the pellet 
in broth.  After more work was done to reduce the size and viscosity of the pellet, the 
experiments were repeated leading to higher recoveries.  However, large cell fragments 
were still trapped in the chip as the sample 
meniscus travelled from the inlet to the outlet, 
particularly around the corners of the chip.  To 
address this problem, a new chip was designed.  
This chip consisted of a wider, straight channel.  
Various channel widths were tested: 0.75 mm, 
1mm, 1.25mm, and 1.5mm.  The 1 mm wide 
channel was chosen, doubling the channel width 
of the serpentine chip.  This reduced restriction on the flow of the sample from the inlet 
to the outlet and decreased the surface area of the channel, reducing bacterial interaction 
A B 
Figure 15. Chip design with 1mm 
channel width. Inlet is at point A, 
outlet is at point B 
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with the wall.  Removing the turns in the channel reduced the amount of sample lost in 
the corners of the chip (see Figure 15). 
To quickly test the efficiency of these chips, they were fabricated on the Carver 
hot press using the method previously described using PMMA pellets rather than Zeonex.  
In the first experiment testing these chips the straight channel chips achieved a recovery 
of around 30% while the recovery of the serpentine chips was around 10%.  The straight 
channeled chips were hot embossed on the Carver, while the serpentine chips were 
injection molded by Protomold.  Neither set of chips was blocked with any blocking 
agent.  The straight channels were twice as wide as the serpentine channel (1mm vs. 0.5 
mm), allowing for less restriction of sample flow.  Given the higher viscosity of the 
samples from the macroconcentrator, the wider channels created much less flow 
resistance, allowing for a cleaner, faster evaporation process (see Figure 16). 
 
Figure 16. Preliminary straight channel experiment using output from the 
macroconcentrator. 
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After this first experiment, another experiment was performed to compare the channel 
geometries in addition to blocking agents and membrane materials.  
 
Figure 17. Output from macroconcentrator comparing the straight and serpentine 
channel geometries and the polypropylene and laminated PTFE membranes. (N=3) 
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Figure 18. Recoveries from output of macroconcentrator comparing unblocked 
chips to chips blocked with 0.5% casein in straight channels, chips blocked with 1% 
BSA and unblocked chips with the sample prepared in 6% BSA. (N=3) 
Figure 17 compares the channel geometry and two different membrane materials: 
polypropylene and a laminated form of the PTFE membrane used in the initial 
experiments.  These membranes consisted of PTFE laminated onto a structural 
polypropylene layer. The surface of the membrane should have been similar to the 
unlaminated PTFE membranes, but they had more structure.  This added structure may 
have aided in preventing the membrane from pulling away from the chip when the 
vacuum was applied, providing less sites for bacterial adhesion. 
Figure 18 shows the comparison of the recoveries from macro-concentrated samples 
when the chips were unblocked and blocked with either BSA or a 0.5% solution of casein 
dissolved in 10xTBS (1.5M NaCl, 0.1M Tris).  Casein is the main protein found in milk.  
Since blocking with milk resulted in above average recoveries, it was thought that casein 
might also result in higher recoveries without contamination from the other components 
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found in milk.  While the casein did result in higher recoveries, the results were not as 
consistent as in the unblocked chips.  This indicates that the casein may not have 
uniformly coated the surfaces of the channels, allowing some chips to have more 
bacterial binding sites than others.  The chips that were blocked with 1% BSA did not 
show improvement over the unblocked case.  It is possible that the residual protein and 
cell debris in the sample has the same capacity to block the chip as a 1% BSA solution.  
The sample to which BSA was added to form a 6% solution improved recovery to around 
60% resulting in the same recovery rate as the chips blocked with 0.5% casein. 
  
39 
7.2 SERS Integration 
As a further means of testing the output from the microconcentrator chip, the 
output samples were tested using Surface Enhanced Raman Spectroscopy.  Currently, 1 
µl of sample is required to be added to the SERS 
substrate.  Several chips were run and 
concentrated down to around 150nl and then the 
outputs of these samples were pooled together to 
produce approximately 1 µl of sample.  The 
samples were added to the SERS substrates, 
allowed to dry for 10 minutes and scanned for 10 
seconds.  The first of these experiments was done with samples prepared in 1%, 3%, and 
6% BSA before concentration.  When the 6% BSA sample was added to the SERS 
substrate, it immediately recrystallized (Figure 19).  A SERS spectrum could not be taken 
because the BSA crystal created a two focal plane effect when viewed under the SERS 
microscope.  When the SERS spectrum was taken (Figure 20), a large protein band 
appeared in the signal due to the high concentration of BSA in the sample.  The blue 
spectrum shows the positive control of the sample.  This is a spectrum typical of MSSA.  
The spectrum is dominated by a large peak at 735 cm-1.  This peak corresponds to 
adenine, one of the major metabolites produced by S. aureus, and other bacterial strains.  
The other peaks in spectrum help to distinguish S. aureus from other related strains.  
Absent from blue spectrum is a band around 450 cm-1.  This band appears in the spectra 
Figure 19. SERS substrate with 
recrystalized sample in BSA. 
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of bacteria prepared in 1% and 3% BSA.  This band is generated by the addition of 
protein to the sample. 
   
Figure 20. SERS spectra of MSSA prepared in 0%, 1%, and 3% BSA before 
concentration. Black vertical line denotes adenine peak at 735 cm-1 and red vertical 
line denotes albumin peak at 450 cm-1. 
The adenine peak is still present in the signal of the sample prepared in 1% BSA.  
However, the smaller secondary peaks on the right side of the spectrum have been greatly 
reduced, thus diminishing the signal-to-noise ratio of the spectrum.  In the 3% BSA case, 
the signal is further reduced, resulting in a lower adenine peak.  This peak has roughly the 
same magnitude as the BSA peak.  From these results, it is clear that preparing samples in 
BSA is not a viable option when using SERS as an identification method.  
To determine the maximum concentration of blocking agent tolerable in the 
sample, BSA was prepared in the following concentrations: 6%, 15%, and 25%.  These 
samples were spiked with high concentrations of BSA to mimic the effects of 
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concentrating both the bacteria and the blocking solution.  Each sample was added to the 
SERS substrate and a spectrum was taken.  The results of this experiment appear in 
Figure 21. 
 
Figure 21. SERS spectra of MSSA spiked into various concentrations of BSA. Black 
vertical line denotes adenine peak at 735 cm-1 and red vertical line denotes albumin 
peak at 450 cm-1. 
Each of the samples denoted in Figure 21 contained approximately 106 cfu of 
MSSA in the one microliter that was added to the SERS substrate.  No significant effect 
due to the BSA is visible in the samples prepared in 6% and 15% BSA.  When the 
samples are prepared in 25% BSA a significant peak at 450 cm-1 and the reduction in the 
adenine peak at 735 cm-1 are seen.  However, at concentrations less than 15%, the BSA 
does not seem to have an adverse effect on the bacterial signal.  The samples prepared in 
6% and 15% BSA produce signals that closely mimic the control done in 0% BSA (DI 
water).  In these signals the adenine peaks are not reduced in magnitude, although in the 
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15% BSA sample, the smaller secondary peaks do appear to suffer some reduction.  The 
6% BSA sample, is a high fidelity representation of the pure bacteria sample; therefore, if 
the concentration of BSA in the output sample is less than 6%, the sample can be 
identified through SERS.  
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Chapter 8: Surface Treatments 
Given the tendency of protein based blocking agents to produce SERS signals, it 
was desirable to modify the microfluidic chips in a way that would prevent bacterial 
adhesion but not detract from the fidelity of the bacterial signal.  This could be 
accomplished in two ways: using a chip coating that would not produce a SERS signal, or 
using a coating that is permanently attached to the chip.  This chapter describes 
commercial and in lab surface modification experiments performed to alter the surface of 
the chip to reduce bacterial adhesion. 
8.1 Hydromer 
Various surface coatings were researched to find a covalently bonded coating that 
would repel bacteria from the chip’s surface while remaining attached to the chip so as 
not to appear in the final sample and produce a SERS signal.  The ideal surface coating 
would be a hydrophilic, negatively charged coating which would prevent hydrophobic 
interactions and repel negatively charged bacteria.  Several surface treatments met these 
criteria; however, many of these coatings were bactericidal.  Viable bacteria are 
necessary to produce a SERS signal; therefore, bactericidal coatings are not desirable for 
this application.  One surface coating that met all criteria was the 7-TS-13 coating 
developed by Hydromer (Branchburg, NJ).  Fifteen serpentine chips were sent to 
Hydromer for surface coating.  To test the efficacy of the surface coating without the 
additional aid of blocking, bacteria samples were prepared in LB. Recoveries were still 
lower than desired with a 28±8%SD recovery for MSSA and 32±3%SD recovery for E. 
coli.   
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8.2 PMMA Surface activation and Silanization 
Oxygen plasma treatments were performed on the PMMA chips using a PVA Te 
Pla Model M4L RF Plasma Processing system.  Polymers typically have low surface 
energy, but can be activated through plasma ashing [48].  These plasma treatments affect 
the surface chemistry of the polymer without affecting the properties of the bulk material.  
The activated surface then has increased affinity for binding to coatings.  Oxygen plasma 
ashing exposes oxygen gas to high power radio waves, ionizing it.  The ionized oxygen 
bombards the surface of the polymer increasing the polar oxygen species content, 
increasing surface hydrophilicity [49].  For example, it was found that treating PMMA 
with oxygen plasma at 200W for 30 seconds increased the oxygen to carbon ratio at the 
surface from 0.31 to 0.58 and lowered the contact angle from 83° to 45°, [48].  Treating 
PMMA with oxygen plasma not only increases surface wettability, but also increases the 
negative charge of the surface [49].   Given the inertness of PMMA, surface activation is 
a necessary first step before a covalent surface coating can be applied [49, 50].  The 
plasma activation reaction is shown in Figure 22.  
 
Figure 22. PMMA surface before and after oxygen plasma activation. 
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Figure 23. Silanization reaction of PMMA surface after oxygen plasma activation. 
 
Silanization treatments were performed to modify the surfaces of the PMMA 
chips.  To increase the affinity of the PMMA chips to bond to the silane, the surface was 
pre-activated through oxygen and argon plasma treatment.  The chips were placed in the 
plasma asher and underwent a 1 minute 400 sccm argon and 200 sccm oxygen plasma 
treatment at 100W.  At the end of this plasma treatment, the chips, previously 
hydrophobic became more hydrophilic and charged.  This plasma treatment was followed 
by a silanization step.  The reaction of this silanization process is shown in Figure 23.  
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The silane is hydrolyzed in water.  The silane reacts with water forming hydroxyl groups 
attached to the silicon atom.  Silanols are formed as the individual silane molecules bond 
with each other, and then deposit on the surface.  The first silanization was with 
trichloro(1H,1H,2H,2H-perfluorooctyl)silane.  This silanization step was performed by 
putting chips channel side up in a vacuum desiccator with a petri dish containing 20 ml of 
trichloro(1H,1H,2H,2H-perfluorooctyl)silane.  The vacuum was applied, evaporating the 
silane and allowing it to deposit on the chips for two hours.  After the silanization, the 
chip’s surface became hydrophobic once again.  In this experiment, 3 chips were 
untreated, 3 underwent plasma treated only, and each silanization was performed on 6 
chips – 3 that had been plasma treated first and 3 that were untreated before silanization.  
A summary of the recoveries in this experiment appears in Figure 24.  The plasma treated 
chips that were not silanized resulted in the highest recovery rates although there was no 
significant difference between treatments.   
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Figure 24. Results of initial in-lab plasma treatment and silanization with 
trichloro(1H,1H,2H,2H-perfluorooctyl)silane.  
Further studies were performed varying the parameters of the plasma treatments.  
The amounts of argon and oxygen used in each treatment could be adjusted by changing 
the duration of the treatment or the flow rate of each gas.  Other parameters that could be 
adjusted were the Ar:O2 ratio and the power used during the treatment.  No increase in 
bacterial recovery was observed by increasing the amount of oxygen used in the 
treatment, implying that the initial treatment conditions fully functionalized the surface of 
the PMMA chips.  However, increasing the power used in the plasma treatment 
significantly decreased the recovery of MSSA (Figure 25 and Figure 26).  It is known 
that over activation of PDMS can lead to surface passivation, so it is possible that a 
similar effect occurs in PMMA. 
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Figure 25. Effects of different plasma O2 amounts on bacterial recovery. 
 
Figure 26. Effects of power used in plasma treatment of PMMA chips with 400 sccm 
Ar, 200 sccm O2 for 1 minute. 
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8.3 Plasma Technology Systems 
Surface treatments were performed as a preliminary study to see if professional 
surface treatments could be financially justified.  The results of the studies in the previous 
section determined that chips would be sent to be professionally surface treated by 
Plasma Technology Systems, LLC (Belmont, CA).  Three hexamethyldisiloxane 
(HMDSO) surface treatments were performed on ten serpentine chips each.  Each 
treatment employed the same cleaning and processing steps but varied the amount of 
oxygen used.  A summary of treatments performed appears in Table 1. 
Table 1. Summary of plasma treatments performed on chips. 
Process Cleaning 
Deposition 
Chemistry Oxygen 
Water Contact 
Angle 
Untreated None None None 74.9° 
Process 1 Argon HMDSO None 101.6° 
Process 2 Argon HMDSO Low 89.52° 
Process 3 Argon HMDSO Medium 90.75° 
 
HMDSO is a siloxane that is often used as an interfacial layer between PMMA and thin 
film coatings because of its high deposition rate and its ability to improve the adhesion 
between the PMMA and the coating [51, 52]. These HMDSO treated chips were tested 
without any additional surface functionalization.  The results of these experiments appear 
in Figure 27.   
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Figure 27. Bacterial recovery in chips treated by Plasma Technology Systems. 
There was no significant difference in recoveries among the three surface treatments 
tested; however, it was noted that the treatments that were better for MSSA were worse 
for E. coli, and those that were better for E. coli were worse for MSSA.  Future studies 
will be devoted to understanding the interactions between the bacteria and the polymer 
surfaces. 
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Chapter 9: Conclusions and Future Work 
9.1 Increased Sample Volume 
To fully accommodate the output of the macroconcentrator without losing 
bacteria, the chip must be redesigned to contain a sample volume of 30 µl, without 
increasing the outside dimensions of the 
chip (15mm x 18mm).  Two new chips 
have been designed and will be evaluated 
for performance (Figure 28) When 
designing these chips, the following 
parameters were considered: surface area 
to volume ratio, the membrane surface area, and the channel width. The surface area to 
volume ratio should be minimized to prevent excessive contact of the bacteria with the 
channel walls.  The membrane surface area should also be minimized as it is the most 
hydrophobic part of the chip and the site of bacterial adhesion. The channel width of the 
diamond shaped channel is 13mm and was designed to create a more linear path for the 
bacteria to travel from the inlet to the outlet.  The channel width of the serpentine channel 
is 2 mm and allows for a meniscus that can span the channel and drag the bacteria from 
the inlet to the outlet.  These chips will be evaluated for recovery rate, evaporation time, 
and integration potential. 
 
 
5mm 
Figure 28. Two potential designs for 30 µl 
chips. 
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9.2 Dialysis Experiments 
To purify the sample and remove unwanted protein contamination, preliminary 
dialysis experiments have been performed.  The dialysis is performed in parallel with the 
evaporation to dialyze protein out of the sample while also concentrating the target 
analyte.  A diagram of the cross section of the evaporation/dialysis fixture is shown in 
Figure 29.  The evaporation system is functionally identical to that previously described.  
A polycarbonate vacuum fixture with a peg array is used to support the chip and 
membrane while convective airflow 
evaporates the sample.  This version of 
the chip has channels that are open on 
both sides.  The evaporation membrane 
is attached to one side of the chip.  On 
the other side of the chip, a dialysis 
membrane is attached using UV curing 
epoxy.  The dialysis membrane is made 
of hydrophilic polycarbonate with 0.050 µm pores.  This pore size allows proteins to 
diffuse out of the sample but prevents the bacteria from doing so.  The dialysis membrane 
is in contact with a 0.9% saline solution.  The volume of this solution is around 20 ml and 
is constantly being stirred by a stir bar, keeping the concentration of protein on the 
dialysis side of the membrane much lower than the concentration of protein in the chip.  
 
 
A 
B 
D 
E F 
C 
Figure 29. Cross section of dialysis 
evaporation fixture. A) Evaporation 
fixture, B) Evaporation membrane, C) 
Chip, D)Dialysis membrane, E) Dialysis 
Reservoir, F) Dialysis Fluid 
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By constantly refreshing the fluid at the membrane interface, the protein is continually 
driven to diffuse out of the chip. 
The microfluidic chips used for dialysis experiments are created by carving the 
channel out of polyolefin sheets using xurography.  This fabrication method produces 
chips that are rougher than those injection molded by Proto Labs, so a reduction in 
recovery rates was expected.  Preliminary experiments were performed using these chips 
by preparing the samples in 6% BSA or by preparing the chips by blocking them with 
0.5% casein for 30 minutes.  The recovery of MSSA and E. coli samples prepared in 6% 
BSA were 52±16%SD and 58±12%SD respectively. 
To test the efficacy of removing the BSA from the sample, a BCA protein assay 
was performed to determine the concentration of the protein in the sample after dialysis 
and concentration.  In the initial experiments performed, 30 µl of 6% BSA was 
concentrated to a final volume of approximately 1 µl. Despite the 30X reduction in 
volume, the BSA concentration stayed approximately the same at 6%.  The experiment 
was repeated, reducing the sample volume to the target volume of around 100 nl and the 
BSA concentration increased slightly to around 7.5%.  To reduce the protein 
concentration in the final sample, the BSA samples were added to the chip and allowed to 
dialyze before reducing the volume of the sample.  The pre-evaporation dialysis time was 
varied from 10 to 40 minutes and the results are summarized in Figure 30. 
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Figure 30. Final BSA concentration vs. dialysis time before concentration. 
By increasing the dialysis time to 40 minutes before beginning volume reduction, 
the final protein concentration was reduced to around 1.5%, also this increased exposure 
time of the bacteria to the chip may have an adverse effect on bacterial recovery.  
However, shorter dialysis times may also reduce the protein concentration to an 
acceptable level (less than 6%) and can be used.  Further experiments will be done to 
optimize bacterial recovery sample purification. 
9.3 Conclusions 
Although high recoveries have been achieved, they have not yet been achieved in 
a way that is compatible with the SERS method of detection.  Further studies on this 
topic will be performed to purify the output sample of the microconcentrator through the 
use of dialysis.  Additionally, studies involving surface modifications of the microfluidic 
chips will also be performed to design a surface that will repel both organisms studied: 
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MSSA and E. coli.  In order to do so, a better understanding of the differences between S. 
aureus and E. coli will be necessary to determine why the surface treatments tested work 
often for one, but not both of the bacteria types.  In addition to understanding the 
differences between the bacteria, an understanding of how they interact with the surfaces 
will also be necessary. 
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